DUBLIN, Nov. 7, 2018 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company
will be webcasting its corporate presentations at four upcoming
investor conferences.
- Stifel Healthcare Conference in New
York, NY on Wednesday, November 14,
2018 at 9:30 a.m. EST /
2:30 p.m. GMT. Bruce Cozadd, chairman and chief executive
officer, will provide an overview of the company and a business and
financial update.
- Jefferies London Healthcare Conference in London on Wednesday,
November 14, 2018 at 9:20 a.m.
GMT / 4:20 a.m. EST.
Iain McGill, senior vice president,
Jazz Pharmaceuticals Europe and rest of world, will provide an
overview of the company and a business and financial update.
- Evercore ISI Healthcare Conference in Boston, MA on Tuesday,
November 27, 2018 at 8:00 a.m.
EST / 1:00 p.m. GMT.
Matt Young, executive vice president
and chief financial officer, will provide an overview of the
company and a business and financial update.
- Piper Jaffray 30th
Annual Healthcare Conference in New York,
NY on Wednesday, November 28,
2018 at 11:00 a.m. EST /
4:00 p.m. GMT. Matt Young, executive vice president and chief
financial officer, will provide an overview of the company and a
business and financial update.
A live audio webcast of each presentation may be accessed from
the Investors section of the Jazz Pharmaceuticals website at
http://www.jazzpharmaceuticals.com. Please connect to the
website prior to the start of the presentation to ensure adequate
time for any software downloads that may be necessary to listen to
the webcast.
An archive of the webcast will be available for at least one
week following the presentation on the Investors section of the
company's website at http://www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is an international biopharmaceutical company
focused on improving patients' lives by identifying, developing and
commercializing meaningful products that address unmet medical
needs. The company has a diverse portfolio of products and
product candidates with a focus in the areas of sleep and
hematology/oncology. In these areas, Jazz Pharmaceuticals
markets Xyrem® (sodium oxybate) oral solution, Erwinaze®
(asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide
sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for
injection in the U.S. and markets Erwinase®, Defitelio®
(defibrotide) and Vyxeos® 44 mg/100 mg powder for concentrate
for solution for infusion in countries outside the U.S. For
country-specific product information, please visit
http://www.jazzpharmaceuticals.com/products. For more
information, please visit http://www.jazzpharmaceuticals.com/ and
follow us on Twitter at @JazzPharma.
Logo-
https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg